Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention

Broadly neutralizing antibodies (bNAbs) are promising agents to prevent HIV infection and achieve HIV remission without antiretroviral therapy (ART). As with ART, bNAb combinations are likely needed to cover HIV's extensive diversity. Not all bNAbs are identical in terms of their breadth, potency, and in vivo longevity (half-life). Given these differences, it is important to optimally select the composition, or dose ratio, of combination bNAb therapies for future clinical studies. We developed a model that synthesizes 1) pharmacokinetics, 2) potency against a wide HIV diversity, 3) interaction models for how drugs work together, and 4) correlates that translate in vitro potency to clinical protection. We found optimization requires drug-specific balances between potency, longevity, and interaction type. As an example, tradeoffs between longevity and potency are shown by comparing a combination therapy to a bi-specific antibody (a single protein merging both bNAbs) that takes the better potency but the worse longevity of the two components. Then, we illustrate a realistic dose ratio optimization of a triple combination of VRC07, 3BNC117, and 10-1074 bNAbs. We apply protection estimates derived from both a non-human primate (NHP) challenge study meta-analysis and the human antibody mediated prevention (AMP) trials. In both cases, we find a 2:1:1 dose emphasizing VRC07 is nearly optimal. Our approach can be immediately applied to optimize the next generation of combination antibody prevention and cure studies. Author summarySome people living with HIV generate antibodies that can neutralize an extremely wide variety of HIV variants. Using these broadly neutralizing antibodies as drugs is an exciting development for HIV prevention and therapy. They are safe and well-tolerated, are relatively long-lasting, and hold the promise of one day being vaccine-induced. As broad as they are, early studies have shown that multiple antibodies will need to be combined to be most effective. Combinations can be complicated because some antibodies neutralize some variants better than others, and some last longer than others. We investigated how to balance these advantages and how to choose the ratios of antibodies to make the best combination drug. Our approach can immediately be used to optimize the coming generations of trials in humans.

Automated summary

Broadly neutralizing antibodies (bNAbs) are a promising drug for the prevention and treatment of HIV. However, due to differences in breadth, potency, and in vivo longevity, it is important to optimize the composition and dose ratio of combination bNAb therapies to enhance efficacy.